Enveric Biosciences has announced the issuance of a new U.S. patent (USPTO Number 12,187,679) covering a novel family of molecules with potential applications in treating sleep and central nervous system $(CNS)$ disorders. This patent enhances the company's intellectual property portfolio and includes selective melatonin receptor-binding compounds, which could be used to target sleep disorders. Among the covered molecules are potential MT1-selective agonists, suggesting promise for innovative sleep therapeutics. The patent further supports Enveric's CNS-focused strategy, targeting high-value therapeutic markets.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。